Federated Hermes’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Federated Hermes’s Portfolio KNTE Stock Details KNTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-585	Closed	-$1.39K	–	2171
2023 Q4	$1.39K	Sell	585 -1,123	-66%	-$1.99K	﹤0.01%	1952
2023 Q3	$2.39K	Buy	+1,708	New	+$4.1K	﹤0.01%	1955
2023 Q1	–	Sell	-4	Closed	-$24	–	2297
2022 Q4	$24	Sell	4 -307,796	-100%	-$2.51M	﹤0.01%	2137
2022 Q3	$3.68M	Hold	307,800	–	–	0.01%	742
2022 Q2	$3.88M	Hold	307,800	–	–	0.01%	749
2022 Q1	$3.47M	Hold	307,800	–	–	0.01%	870
2021 Q4	$5.45M	Hold	307,800	–	–	0.01%	790
2021 Q3	$7.09M	Hold	307,800	–	–	0.01%	740
2021 Q2	$7.17M	Hold	307,800	–	–	0.01%	746
2021 Q1	$9.59M	Buy	307,800 +57,800	+23%	+$2.01M	0.02%	670
2020 Q4	$9.95M	Buy	+250,000	New	+$10M	0.02%	642

Other funds holding KNTE

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Federated Hermes's KNTE Position: Q1 2024 in Review

Federated Hermes sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q1 2024, closing a stake of 585 shares — an estimated $1.39K sold.

Federated Hermes first reported a position in KNTE in Q4 2020 and held it in 11 quarters. The position peaked at $9.95M in Q4 2020. 56 funds tracked by Wall St. Rank hold KNTE as of Q1 2024.

Federated Hermes reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Federated Hermes sold 585 Kinnate Biopharma Inc. Common Stock shares in Q1 2024, an estimated $1.39K.
Federated Hermes first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 11 quarters.
Federated Hermes's Kinnate Biopharma Inc. Common Stock position peaked at $9.95M in Q4 2020.
56 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q1 2024.

Based on Federated Hermes's 13F filing for Q1 2024, filed 14 May 2024.